Huaxiang Xu - Search Results

Year	Number of Results
2008	1
2009	1
2010	6
2011	4
2012	2
2013	4
2014	3
2015	3
2016	5
2017	3
2018	11
2019	13
2020	10
2021	7
2022	9
2023	4
2024	1

1

The role of collagen in cancer: from bench to bedside.

Xu S, Xu H, Wang W, Li S, Li H, Li T, Zhang W, Yu X, Liu L. Xu S, et al. Among authors: xu h. J Transl Med. 2019 Sep 14;17(1):309. doi: 10.1186/s12967-019-2058-1. J Transl Med. 2019. PMID: 31521169 Free PMC article. Review.

2

Angiogenesis in pancreatic cancer: current research status and clinical implications.

Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX, Yu XJ, Liu L. Li S, et al. Angiogenesis. 2019 Feb;22(1):15-36. doi: 10.1007/s10456-018-9645-2. Epub 2018 Aug 24. Angiogenesis. 2019. PMID: 30168025 Review.

3

Tumor Microenvironment Responsive CD8⁺ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Cancer.

Chen Q, Yin H, He J, Xie Y, Wang W, Xu H, Zhang L, Shi C, Yu J, Wu W, Liu L, Pu N, Lou W. Chen Q, et al. Among authors: xu h. Adv Sci (Weinh). 2023 Nov;10(33):e2302498. doi: 10.1002/advs.202302498. Epub 2023 Oct 22. Adv Sci (Weinh). 2023. PMID: 37867243 Free PMC article.

4

The Significance of Liquid Biopsy in Pancreatic Cancer.

Qi ZH, Xu HX, Zhang SR, Xu JZ, Li S, Gao HL, Jin W, Wang WQ, Wu CT, Ni QX, Yu XJ, Liu L. Qi ZH, et al. J Cancer. 2018 Sep 8;9(18):3417-3426. doi: 10.7150/jca.24591. eCollection 2018. J Cancer. 2018. PMID: 30271504 Free PMC article. Review.

5

Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer.

Xu JZ, Wang WQ, Zhang SR, Xu HX, Wu CT, Qi ZH, Gao HL, Li S, Ni QX, Yu XJ, Liu L. Xu JZ, et al. Curr Med Chem. 2019;26(40):7196-7211. doi: 10.2174/0929867325666180413101722. Curr Med Chem. 2019. PMID: 29651946 Review.

6

The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis.

Li H, Jiang W, Zhang SR, Li PC, Li TJ, Jin W, Xu HX, Yu XJ, Liu L. Li H, et al. Oncogene. 2023 May;42(18):1453-1465. doi: 10.1038/s41388-023-02647-0. Epub 2023 Mar 15. Oncogene. 2023. PMID: 36922676 Free PMC article.

7

Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer.

Ye L, Jin K, Liao Z, Xiao Z, Xu H, Lin X, Li H, Li T, Zhang W, Han X, Wang W, Gao H, Liu L, Wu W, Yu X. Ye L, et al. Among authors: xu h. EBioMedicine. 2022 May;79:104016. doi: 10.1016/j.ebiom.2022.104016. Epub 2022 Apr 25. EBioMedicine. 2022. PMID: 35483273 Free PMC article.

8

EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms.

Xiao Z, Xu H, Strosberg JR, Lu R, Zhu X, Deng S, Ding L, Ni Q, Warshaw AL, Yu X, Luo G. Xiao Z, et al. Among authors: xu h. Int J Cancer. 2023 Jul 1;153(1):164-172. doi: 10.1002/ijc.34499. Epub 2023 Mar 17. Int J Cancer. 2023. PMID: 36891979

9

Significance of caveolin-1 regulators in pancreatic cancer.

Chen T, Liu L, Xu HX, Wang WQ, Wu CT, Yao WT, Yu XJ. Chen T, et al. Asian Pac J Cancer Prev. 2013;14(8):4501-7. doi: 10.7314/apjcp.2013.14.8.4501. Asian Pac J Cancer Prev. 2013. PMID: 24083692 Free article. Review.

10

Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.

Li T, Li H, Li S, Xu S, Zhang W, Gao H, Xu H, Wu C, Wang W, Yu X, Liu L. Li T, et al. Among authors: xu h. Cancer Med. 2019 Sep;8(11):5223-5231. doi: 10.1002/cam4.2430. Epub 2019 Jul 3. Cancer Med. 2019. PMID: 31339230 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year